Assessment of Clinical Outcome of Patients With Primary Myelofibrosis Treated ？With Ruxolitinib in the Real-World Practice | Alwan | Global Journal of Health Science | CCSE

BACKGROUND: Primary myelofibrosis (PMF) is a disease that characterized by bone ？marrow fibrosis which ？may ？result sometime in cytopenias and extramedullary ？hematopoiesis causing massive ？splenomegaly. Ruxolitinib (Rux) therapy that targeted ？Janus Kinase-2 receptor and approved ？for treatment of primary myelofibrosis. ？ OBJECTIVE: evaluate the clinical ？outcome of patients with ？primary myelofibrosis ？receiving Ruxolitinib treatment as ？a compassionate use program ？and compare this treatment with the best ？available treatment (BAT).？ METHODS: ？This is a retrospective case series conducted at the national ？center of hematology /？？Mustansiriyah University. The enrollment of patients started ？in May 2014 and ended in May ？？2017. There were ？？22 patients diagnosed with PMF (7 on ？the Ruxolitinib arm and 15 on best ？available treatment arm). The ？treatment response ？was evaluated according to consensus criteria ？of IWG-MRT 2013 in primary ？？myelofibrosis. RESULTS: In this study 3 out of 7 patients on Ruxolitinib arm showed reduction in spleen size and reduction in anemia. In addition to ？that 4 patients ？showed clinical response specifically in spleen ？size (with 65% reduction from baseline during the first three months of treatment). CONCLUSION: Rux is effective and safe to treating ？primary myelofibrosis with ？symptomatic splenomegaly